SC
MRNA icon

Savant Capital’s Moderna MRNA Stock Holding History

Savant Capital’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,338
Closed -$278K – 1438
2024
Q2 		$278K Sell
2,338
-929
-28% -$118K ﹤0.01% 1008
2024
Q1 		$348K Buy
3,267
+223
+7% +$22.5K ﹤0.01% 850
2023
Q4 		$303K Sell
3,044
-290
-9% -$24.4K ﹤0.01% 701
2023
Q3 		$344K Sell
3,334
-740
-18% -$82.5K 0.01% 614
2023
Q2 		$495K Buy
4,074
+1,703
+72% +$227K 0.01% 510
2023
Q1 		$364K Buy
2,371
+258
+12% +$42.6K 0.01% 545
2022
Q4 		$380K Buy
2,113
+390
+23% +$63.8K 0.01% 410
2022
Q3 		$204K Buy
+1,723
New +$261K 0.01% 513
2022
Q2 		– Sell
-1,306
Closed -$225K – 578
2022
Q1 		$225K Buy
1,306
+132
+11% +$22.2K 0.01% 522
2021
Q4 		$298K Buy
+1,174
New +$343K 0.01% 452

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Savant Capital's MRNA Position: Q3 2024 in Review

Savant Capital sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,338 shares — an estimated $278K sold.

Savant Capital first reported a position in MRNA in Q4 2021 and held it in 10 quarters. The position peaked at $495K in Q2 2023. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Savant Capital reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Savant Capital sold 2,338 Moderna shares in Q3 2024, an estimated $278K.
  • Savant Capital first reported a position in Moderna in Q4 2021 and held it in 10 quarters.
  • Savant Capital's Moderna position peaked at $495K in Q2 2023.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Savant Capital's 13F filing for Q3 2024, filed 4 Nov 2024.